NCT03949517View on ClinicalTrials.gov

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions
Prostate Cancer
Interventions
DRUG

68-Ga RM2

Radioactive agent

DRUG

68-Ga PSMA11

Radioactive agent

DEVICE

Investigational software and coils in PET/MR Scan

Investigational software and coils in PET/MR Scan by General Electric Healthcare

PROCEDURE

PET/MRI

Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

General Electric

INDUSTRY

lead

Andrei Iagaru

OTHER

NCT03949517 - 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy | Biotech Hunter | Biotech Hunter